STNE, CVS, KT, KB and USNA stand out in August for low P/B ratios and strong growth forecasts, making them value stock contenders.
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health boosts 2025 EPS guidance again as Health Care Benefits and PBM businesses drive growth.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.
CVS is focusing heavily on technology-led care after posting solid Q2 earnings. “We are building momentum as we navigate what continues to be a dynamic and evolving environment,” Chief Executive David Joyner told analysts on an earnings call Thursday (July 31), crediting the company's “diversified business” for offsetting swings in medical costs.
CVS Health beats on Q2 earnings and raises 2025 EPS outlook, lifting shares nearly 8% on strong segment growth and margin gains.
Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The company boosts its full-year guidance range for adjusted earnings on the heels of a strong second quarter.
Shares of CVS Health (CVS) jumped in premarket trading Thursday after the health care giant posted better-than-expected second-quarter results and lifted its full-year adjusted profit forecast.
CVS Health (CVS) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.83 per share a year ago.
CVS Health reported second-quarter earnings and revenue that topped estimates and raised its adjusted profit outlook. CVS CEO David Joyner pointed to strength in its retail pharmacy business and some improvement in its insurance unit, Aetna, which is grappling with higher medical costs.